Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells

Bone Marrow Transplantation

Volumn 45, Issue 2, 2010, Pages 349-353

  Lioznov, M ^a   El Cheikh, J ^b   Hoffmann, F ^a   Hildebrandt, Y ^a   Ayuk, F ^a   Wolschke, C ^a   Atanackovic, D ^a   Schilling, G ^a   Badbaran, A ^a   Bacher, U ^a   Fehse, B ^a   Zander, A R ^a   Blaise, D ^b   Mohty, M ^c   Kroger N ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b INSTITUT PAOLI CALMETTES   (France)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

Allo SCT; Dose reduced conditioning; Lenalidomide; Multiple myeloma; NK cells

Indexed keywords

BORTEZOMIB; CD158H ANTIGEN; CD226 ANTIGEN; CD94 ANTIGEN; INTERLEUKIN 7 RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; LENALIDOMIDE; LYMPHOCYTE ANTIGEN; NKP30 ANTIGEN; NKP44 ANTIGEN; NKP46 ANTIGEN; STEROID; UNCLASSIFIED DRUG;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW TOXICITY; BRAIN INFARCTION; CANCER RELAPSE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MONITORING; FATIGUE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; INFECTION; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE CRAMP; NATURAL KILLER CELL; NEUROLOGIC DISEASE; NEUTROPENIA; PRIORITY JOURNAL; SALVAGE THERAPY; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA-DR ANTIGENS; HUMANS; KILLER CELLS, NATURAL; LEUKOPENIA; MULTIPLE MYELOMA; RECURRENCE; SALVAGE THERAPY; T-LYMPHOCYTES; THALIDOMIDE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 76749162262     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.155     Document Type: Article

References (18)

1. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447-3454.
2. Krö ger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: 755-760.
3. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356: 1110-1120.
4. Ayuk F, Shimoni A, Nagler A, Schwerdtfeger R, Kiehl M, Sayer HG et al. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia 2004; 18: 659-662.
5. Krö ger N, Krü ger W, Renges H, Zabelina T, Stute N, Jung R et al. Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma. Br J Haematol 2001; 112: 421-423.
6. Krö ger N, Zabelina T, Ayuk F, Atanackovic D, Schieder H, Renges H et al. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol 2006; 34: 770-775.
7. Krö ger N, Shimoni A, Zagrivnaja M, Ayuk F, Lioznov M, Schieder H et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004; 104: 3361-3363.
8. van de Donk NW, Krö ger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood 2006; 107: 3415-3416.
9. Mohty M, Attal M, Marit G, Bulabois CE, Garban F, Gratecos N et al. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Socié té Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC). Bone Marrow Transplant 2005; 35: 165-169.
10. Bladé J, Samson D, Reece D, Apperley J, Bjö rkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
11. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA et al. Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133-2142.
12. Dimopoulos M, Spencer A, AttalM, Prince HM, Harousseau JL, Dmoszynska A et al. Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132.
13. Minnema MC, van der Veer MS, Aarts T, Emmelot M, Mutis T, Lokhorst HM. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4(+)Foxp3(+) T cells. Leukemia 2009; 23: 605-607.
14. Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005; 128: 192-203.
15. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210-216.
16. Beyer M, Kochanek M, Giese T, Endl E, Weihrauch MR, Knolle PA et al. In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 2006; 107: 3940-3949. E-pub 2006 Jan 12.
17. Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006; 108: 1291-1297.
18. Atanackovic D, Cao Y, Luetkens T, Panse J, Faltz C, Arfsten J et al. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation. Haematologica 2008; 93: 423-430.